Stoke Therapeutics: Morgan Stanley reports 4.9% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Stoke Therapeutics, Inc. (STOK) common stock is the subject of an amended ownership report listing Morgan Stanley with 3,177,169 beneficially owned shares (4.9%) and Morgan Stanley Capital Services LLC with 2,653,126 shares (4.1%). Each reporting person stated it had ceased to be the beneficial owner of more than 5% of the class.
Key Figures
Key Terms
beneficially owned technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.